Abstract
AIM - To measure plasma ANP in preterm infants with a clinically apparent PDA at diagnosis and after closure with indomethacin.
METHOD - Arterial AMP was measured in 15 preterm infants with clinical and echocardiography evidence of a PDA. PDA closure was confirmed by echocardiography. 8 controls with no clinical evidence of a PDA had ANP levels measured up to 3 times daily between days 1 and 8. Plasma ANP was measured by radioimmunoassay.
RESULTS - Study babies were 25-32 weeks of gestation, birthweight 0.630-1.820 kg, controls were 25-29 weeks of gestation, birth-weight 0.691-1.334 kg. Plasma ANP was significantly higher in infants before duct closure with indomethacin, median 1422, range 158-4590 pg/ml than after, median 279 range 62-1035 pg/ml (p<0.01). One infants PDA closed spontaneously, his ANP (264-495) remained within the control range median 224 range 62-808 pg/ml.
DISCUSSION - This study has demonstrated that infants in whom indomethacin treatment is clinically indicated have high plasma AMP levels. In the future ANP measurement levels nay have a role in deciding the need for and the timing of indomethacin treatment.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weir, F., Smith, A., Jeffery, S. et al. 94 Atrial Natriuretic Peptide (ANP) in Preterm Infant.With Patent Ductus Arteriosus (PDA). Pediatr Res 28, 292 (1990). https://doi.org/10.1203/00006450-199009000-00118
Issue Date:
DOI: https://doi.org/10.1203/00006450-199009000-00118